Literature DB >> 16374884

Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children.

Roula Hourani1, Alena Horská, Sait Albayram, Larry J Brant, Elias Melhem, Kenneth J Cohen, Peter C Burger, John D Weingart, Benjamin Carson, Moody D Wharam, Peter B Barker.   

Abstract

PURPOSE: To investigate whether in vivo proton magnetic resonance spectroscopic imaging (MRSI) can differentiate between 1) tumors and nonneoplastic brain lesions, and 2) high- and low-grade tumors in children.
MATERIALS AND METHODS: Thirty-two children (20 males and 12 females, mean age = 10 +/- 5 years) with primary brain lesions were evaluated retrospectively. Nineteen patients had a neuropathologically confirmed brain tumor, and 13 patients had a benign lesion. Multislice proton MRSI was performed at TE = 280 msec. Ratios of N-acetyl aspartate/choline (NAA/Cho), NAA/creatine (Cr), and Cho/Cr were evaluated in the lesion and the contralateral hemisphere. Normalized lesion peak areas (Cho(norm), Cr(norm), and NAA(norm)) expressed relative to the contralateral hemisphere were also calculated. Discriminant function analysis was used for statistical evaluation.
RESULTS: Considering all possible combinations of metabolite ratios, the best discriminant function to differentiate between nonneoplastic lesions and brain tumors was found to include only the ratio of Cho/Cr (Wilks' lambda, P = 0.012; 78.1% of original grouped cases correctly classified). The best discriminant function to differentiate between high- and low-grade tumors included the ratios of NAA/Cr and Cho(norm) (Wilks' lambda, P = 0.001; 89.5% of original grouped cases correctly classified). Cr levels in low-grade tumors were slightly lower than or comparable to control regions and ranged from 53% to 165% of the control values in high-grade tumors.
CONCLUSION: Proton MRSI may have a promising role in differentiating pediatric brain lesions, and an important diagnostic value, particularly for inoperable or inaccessible lesions. Published 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16374884     DOI: 10.1002/jmri.20480

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  17 in total

Review 1.  Metabolomic signature of brain cancer.

Authors:  Renu Pandey; Laura Caflisch; Alessia Lodi; Andrew J Brenner; Stefano Tiziani
Journal:  Mol Carcinog       Date:  2017-07-17       Impact factor: 4.784

2.  2-D magnetic resonance spectroscopic imaging of the pediatric brain using compressed sensing.

Authors:  Rohini Vidya Shankar; Houchun H Hu; Nutandev Bikkamane Jayadev; John C Chang; Vikram D Kodibagkar
Journal:  Pediatr Radiol       Date:  2019-08-28

3.  Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells.

Authors:  Tariq Shah; Flonne Wildes; Marie-France Penet; Paul T Winnard; Kristine Glunde; Dmitri Artemov; Ellen Ackerstaff; Barjor Gimi; Samata Kakkad; Venu Raman; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2010-07       Impact factor: 4.044

4.  Advanced MR imaging and 18F-DOPA PET characteristics of H3K27M-mutant and wild-type pediatric diffuse midline gliomas.

Authors:  Arnoldo Piccardo; Domenico Tortora; Samantha Mascelli; Mariasavina Severino; Gianluca Piatelli; Alessandro Consales; Marco Pescetto; Veronica Biassoni; Elisabetta Schiavello; Michela Massollo; Antonio Verrico; Claudia Milanaccio; Maria Luisa Garrè; Andrea Rossi; Giovanni Morana
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-27       Impact factor: 9.236

Review 5.  The Potential of Metabolic Imaging.

Authors:  Valentina Di Gialleonardo; David M Wilson; Kayvan R Keshari
Journal:  Semin Nucl Med       Date:  2016-01       Impact factor: 4.446

Review 6.  Imaging of brain tumors: MR spectroscopy and metabolic imaging.

Authors:  Alena Horská; Peter B Barker
Journal:  Neuroimaging Clin N Am       Date:  2010-08       Impact factor: 2.264

7.  Lack of choline elevation on proton magnetic resonance spectroscopy in grade I-III gliomas.

Authors:  Sanjeev Chawla; Seung-Cheol Lee; Suyash Mohan; Sumei Wang; MacLean Nasrallah; Arastoo Vossough; Jaroslaw Krejza; Elias R Melhem; S Ali Nabavizadeh
Journal:  Neuroradiol J       Date:  2019-05-03

8.  Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.

Authors:  Giovanni Morana; Arnoldo Piccardo; Matteo Puntoni; Paolo Nozza; Armando Cama; Alessandro Raso; Samantha Mascelli; Michela Massollo; Claudia Milanaccio; Maria Luisa Garrè; Andrea Rossi
Journal:  Neuro Oncol       Date:  2015-09-23       Impact factor: 12.300

9.  Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors.

Authors:  Roy E Strowd; Mackenzie C Cervenka; Bobbie J Henry; Eric H Kossoff; Adam L Hartman; Jaishri O Blakeley
Journal:  Neurooncol Pract       Date:  2015-05-26

10.  Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults?

Authors:  R Hourani; L J Brant; T Rizk; J D Weingart; P B Barker; A Horská
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-30       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.